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Summary
Background Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases 
of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months 
of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefit from antibiotic prophylaxis 
to prevent infection, and to investigate the effect on antibiotic-resistant organism carriage and health care-associated 
infections in patients with newly diagnosed myeloma.
Methods TEAMM was a prospective, multicentre, double-blind, placebo-controlled randomised trial in patients aged 
21 years and older with newly diagnosed myeloma in 93 UK hospitals. All enrolled patients were within 14 days of 
starting active myeloma treatment. We randomly assigned patients (1:1) to levofloxacin or placebo with a computerised 
minimisation algorithm. Allocation was stratified by centre, estimated glomerular filtration rate, and intention to 
proceed to high-dose chemotherapy with autologous stem cell transplantation. All investigators, patients, laboratory, 
and trial co-ordination staff were masked to the treatment allocation. Patients were given 500 mg of levofloxacin (two 
250 mg tablets), orally once daily for 12 weeks, or placebo tablets (two tablets, orally once daily for 12 weeks), with dose 
reduction according to estimated glomerular filtration rate every 4 weeks. Follow-up visits occurred every 4 weeks up 
to week 16, and at 1 year. The primary outcome was time to first febrile episode or death from all causes within the 
first 12 weeks of trial treatment. All randomised patients were included in an intention-to-treat analysis of the primary 
endpoint. This study is registered with the ISRCTN registry, number ISRCTN51731976, and the EU Clinical Trials 
Register, number 2011-000366-35.
Findings Between Aug 15, 2012, and April 29, 2016, we enrolled and randomly assigned 977 patients to receive 
levofloxacin prophylaxis (489 patients) or placebo (488 patients). Median follow-up was 12 months (IQR 8–13). 
95 (19%) first febrile episodes or deaths occurred in 489 patients in the levofloxacin group versus 134 (27%) in 
488 patients in the placebo group (hazard ratio 0·66, 95% CI 0·51–0·86; p=0·0018. 597 serious adverse events were 
reported up to 16 weeks from the start of trial treatment (308 [52%] of which were in the levofloxacin group and 
289 [48%] of which were in the placebo group). Serious adverse events were similar between the two groups except for 
five episodes (1%) of mostly reversible tendonitis in the levofloxacin group.
Interpretation Addition of prophylactic levofloxacin to active myeloma treatment during the first 12 weeks of therapy 
significantly reduced febrile episodes and deaths compared with placebo without increasing health care-associated 
infections. These results suggest that prophylactic levofloxacin could be used for patients with newly diagnosed 
myeloma undergoing anti-myeloma therapy.
Funding UK National Institute for Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Myeloma is a cancer of bone marrow plasma cells that 
causes anaemia, skeletal damage, renal impairment, and 
profound immunodeficiency,1 and the median age at 
diagnosis is 70 years.2,3 Myeloma accounts for 2% of all 
cancers in the UK.4 Substantial advances in anti-myeloma 
therapy have improved survival to 50% at 5 years; 
however, infection contributes to death in a fifth of 
patients with myeloma.1,2,5,6 The risk of infection is 
greatest in the first 3 months after diagnosis, with a 
third of patients suffering serious bacterial infection, 
and infection contributing to half of early mortality.7–9 
Despite some reduction in early deaths with use of novel 
anti-myeloma agents,5 early mortality remains a problem 
and population data for England in 2011–15 showed that 
5% of 22 504 patients newly diagnosed with myeloma 
died within the first month of diagnosis, and 21% within 
the first 12 months.9 Antimicrobial prophylaxis might 
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reduce death from infections, since it has been shown to 
improve survival in patients with prolonged neutro-
penia.10 However, concerns about increased antibiotic 
resistance,11,12 drug-related side-effects, and the risk of 
health care-associated infections13 mean the use of 
quinolone prophylaxis remains controversial.14–17
Although the profile of bacterial infections is similar to 
that seen in neutropenia, most infections in patients with 
myeloma are not associated with low neutrophil counts 
but arise because of immunodeficiency, encom passing 
reduced integrity of barriers and reduced competence of 
both innate and adaptive immunity. Given this difference 
and there being, to our knowledge, only two small 
inconclusive randomised controlled trials of antimicrobial 
prophylaxis in myeloma so far,18,19 and considering the 
increasing concern of health care-associated infections, 
there was ambivalence for the use of antimicrobial 
prophylaxis in patients newly diagnosed with myeloma in 
the UK.18,19 Here, we report the results of the tackling early 
morbidity and mortality in myeloma (TEAMM) trial, 
which assessed the benefit of 12 weeks of levofloxacin 
prophylaxis and the effect on resistant organism carriage 
and health care-associated infections in patients with 
newly diagnosed myeloma.
Methods
Study design and participants
TEAMM was a multicentre, double-blind, placebo-
controlled, randomised, phase 3 trial done in 93 UK 
hospitals (appendix pp 1–4). Eligible patients were aged 
21 years and older with newly diagnosed, symptomatic 
myeloma based on internationally agreed criteria,20,21 
within 14 days of starting a programme of anti-myeloma 
therapy. All performance statuses were permitted with 
no indication of life expectancy specified. Patients with 
the following characteristics were ineligible for this trial: 
contraindication to levofloxacin (ie, known to have 
sensitivity or allergy to levofloxacin or other quinolones, 
a history of tendon disorders related to fluoroquinolone 
administration, receiving other pro phylactic antibiotic 
treatment [excluding pneumocystis prophylaxis if 
regarded as essential], receiving amiodarone or arsenic 
trioxide, and on active antiepileptic treatment); women of 
childbearing age who were not willing to use appropriate 
methods of contraception to prevent pregnancy; women 
who were breastfeeding; patients thought to have 
mandatory requirement for prophyl actic antibiotics (with 
the exception of pneumocystis prophylaxis if regarded as 
essential); and previous (<5 years since diagnosis) or 
concurrent active malig nancies, except surgically 
removed basal or squamous cell carcinoma of the skin, 
treated carcinoma in-situ of the breast or cervix, or 
incidental histological finding of prostate cancer (TNM 
stage T1a or 1b). Patients with remote histories (>5 years) 
of other cured (on no active treatment for the previous 
malignancy) malignancies were eligible. Patients were 
recruited by clinicians and research teams at their local 
hospitals.
The study was approved by the UK Coventry and 
Warwickshire Multi-Research Ethics Committee on 
Laboratory, Heart of England 
NHS Trust, Birmingham, UK 
(Prof P Hawkey MD); 
and Patient Advocacy, 
Myeloma UK, Edinburgh UK 
(E Low BA)
Correspondence to: 
Prof Mark T Drayson, School of 
Immunity and Infection, 
University of Birmingham, 
Birmingham B15 2TT, UK 
m.t.drayson@bham.ac.uk
Research in context
Evidence before this study
We searched PubMed for research articles published in English 
with the search terms “cancer”, “myeloma”, “multiple myeloma”, 
“early mortality, “infection”, “antibiotic prophylaxis”, 
“quinolones”, and “levofloxacin”. No date restrictions were 
applied. We found that the risk of infection was greatest in the 
first 3 months after diagnosis of myeloma, with a third of 
patients suffering serious bacterial infection and infection, 
contributing to half of early mortality. Antimicrobial 
prophylaxis, especially with quinolones, is effective at reducing 
infections and mortality in patients with neutropenia. However, 
concerns about increased antibiotic resistance and the risk of 
health care-associated infections linked to antibiotic prophylaxis 
means its application remains controversial. Despite this 
increasing concern about health care-associated infections, 
to our knowledge, there have been only two small inconclusive 
randomised controlled trials of antimicrobial prophylaxis in 
patients with myeloma, meaning a study of antimicrobial 
prophylaxis in patients with newly diagnosed myeloma was 
warranted.
Added value of this study
To our knowledge, this is the first double-blind randomised 
placebo-controlled trial of antibiotic prophylaxis in patients 
with myeloma and the first trial to show improved survival and 
reduced infections. The trial was designed to map onto current 
standard practice in the UK, recruiting 977 patients from 
93 hospitals and allowing a choice of anti-myeloma therapy, 
with most patients receiving newer anti-myeloma therapies. 
Examination of stool samples and nasal swabs every 4 weeks 
revealed no difference between the levofloxacin group and the 
placebo group for new acquisitions of Clostridium difficile, 
meticillin-resistant Staphylococcus aureus, and 
extended-spectrum β-lactamase-positive Gram-negative rods 
when assessed up to 16 weeks. The results of this study suggest 
that the benefits of levofloxacin prophylaxis outweigh the 
perceived risks in patients with newly diagnosed myeloma.
Implications of all the available evidence
To our knowledge, this is the largest trial to date of levofloxacin 
prophylaxis in patients newly diagnosed with myeloma and 
provides the best available evidence to suggest that 
levofloxacin prophylaxis could be a standard of care in the first 
12 weeks after diagnosis.
See Online for appendix
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July 29, 2011. All patients provided written, informed 
consent.
Randomisation and masking
We randomly assigned patients (1:1) to levofloxacin or 
placebo with a computerised minimisation algorithm 
that generated a trial number and drug pack allocation 
for each patient. Allocation was stratified by centre, 
estimated glomerular filtration rate (>50 mL/min, 
20–50 mL/min, and <20 mL/min), and intention to 
proceed to high-dose chemotherapy with autologous 
stem cell transplantation (yes vs no). The trial statistician 
allocated the term active or placebo in a 50:50 split to a 
list of 1500 randomly generated drug pack numbers. The 
password-protected list was sent to the drug packaging 
company who put the active drugs or placebo in correctly 
labelled packs. This list was then used to build the 
bespoke randomisation and drug inventory system. 
Participants were enrolled by research staff at each centre 
who used a dedicated randomisation phone line at the 
clinical trials unit and after undergoing eligibility checks 
were allocated a drug pack number. All investigators, 
patients, laboratory, and trial co-ordination staff were 
masked to the treatment allocation. Tablets were manu-
factured specifically for the trial and packaged in identical 
blister packs by Modepharma (Beckenham, UK). Sample 
drug packs were tested independently to confirm the 
active drug and placebo were correctly coded.
Procedures
Symptomatic myeloma was diagnosed according to 
British Committee for Standards in Haematology and 
UK Myeloma Forum Guidelines on the Management 
and Diagnosis of Multiple Myeloma20,21 with immuno-
fixation of serum and urine to identify monoclonal 
immunoglobulin, measurement of bone marrow plasma 
cells, and identification of myeloma-related end organ 
damage.
Patients were given 500 mg of levofloxacin (two 250 mg 
tablets), orally once daily for 12 weeks, or placebo tablets 
(two tablets, orally once daily for 12 weeks), with dose 
reduction according to estimated glomerular filtration 
rate every 4 weeks. Adherence to trial treatment was 
monitored with patient diary cards. Other prophylactic 
antibiotics were prohibited, except for the use of low-
dose co-trimoxazole to prevent pneumocystis pneumonia 
according to local practice. Anti-myeloma therapy was 
given according to local practice.
We assessed nasal swabs and stool samples collected at 
baseline, 4 weeks, 8 weeks, 12 weeks, and 16 weeks as per 
protocol for carriage of meticillin-resistant Staphylococcus 
aureus (MRSA), Clostridium difficile, and extended-
spectrum β-lactamase (ESBL) Gram-negative coliforms. 
We identified toxigenic strains of C difficile by culture and 
ribotyping. We identified ESBL Gram-negative coliforms 
from faecal screens and clinical specimens by culture on 
selective agar and genotyped for CTX-M β-lactamase 
genes by denaturing high-performance liquid 
chromatography. We cultured nasal swabs for MRSA and 
isolates were typed and stored.
We assessed myeloma activity and markers of 
immunocompetence in blood and urine collected at 
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 
1 year. Markers of immunocompetence assessed were 
monoclonal and polyclonal immunoglobulins, antibodies 
specific to a range of bacterial and viral target antigens, 
markers of inflammation, and cytokines.
Capture of febrile episodes was via hospital records or 
patient diary cards as patients were asked to self-report 
temperature daily or when they felt unwell. All 
hospitalisations were cross-referenced, and notes were 
checked for any additional information. Patients were 
treated according to local practice. Management of 
neutropenic sepsis is relatively standardised across 
the UK according to National Institute for Health and 
Care Excellence guidelines.22
Deaths were reviewed by a masked inde pendent 
clinical reviewer not linked to the trial. Cause of death 
was ascertained from information sent by the centre 
regarding cause of death and disease status, and review 
of previous serious adverse events and myeloma 
response on blood samples received. Assessments were 
done by two trial clinicians who were masked to the trial 
intervention.
Outcomes
The primary outcome was time to first febrile episode or 
death from all causes within the first 12 weeks of trial 
treatment. A febrile episode was defined as a single oral 
temperature of 38°C or higher that caused the patient to 
be given anti-infectives. A single febrile episode was 
defined as the initial febrile event and any subsequent 
fevers until that course of anti-infectives was stopped.
Secondary outcomes assessed from start of trial 
treatment to 12 weeks were the number of deaths and 
infection-related deaths; number of non-febrile infections 
(clinically suspected infections without a temperature 
≥38°C or higher and where anti-infectives were 
prescribed); number of days in hospital; number of days 
in hospital on anti-infective; carriage and invasive 
infections with MRSA, C difficile, and ESBL Gram-
negative coliforms; patient characteristics, steroid usage, 
and indices of immunocompetence and their relation to 
colonisation by and development of infection from 
S aureus, C difficile, and ESBL Gram-negative coliforms 
and non-health care-associated infection and Eastern 
Cooperative Oncology Group performance status; 
number of clinically documented total infections, 
episodes of severe sepsis (Common Terminology Criteria 
for Adverse Events grade 3 or 4), and suspected infections; 
incidence of microbiologically proven infections, the 
pathogens, and their susceptibility to antibiotics; days on 
antibiotic therapy for treatment of infection; and 
response to anti-myeloma therapy and its relationship to 
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infection. Secondary outcomes from randomisation to 
beyond 12 weeks were carriage and invasive infections 
with S aureus, C difficile, and ESBL Gram-negative 
coliforms between 12 weeks and 16 weeks to assess for 
delayed effects from the intervention that was stopped at 
12 weeks; response to anti-myeloma therapy at 16 weeks; 
quality of life (4-weekly questionnaires up to 16 weeks); 
health economics (daily diary card that captures elements 
of health resource use combined with information 
captured on the case report form); and overall survival. 
Number of days in hospital, days on antibiotic therapy 
for treatment of infection, reponse to anti-myeloma 
therapy at 16 weeks, health economics and quality of life, 
more detailed microbiology, and in-depth analysis on 
patient measures of immunocompetence and relation to 
infection, and depth of myeloma response in relation to 
antibiotic use, will be reported separately.
Statistical analysis
Our power calculations assumed that 30% of patients 
would have a febrile episode or death in the first 
12 weeks and levofloxacin would reduce this to 20%; 
thus, 800 patients (400 in each study group) would 
allow differences in excess of 10% to be detected with 
90% power using a two-sided test at 5% significance. 
A pre-planned early stopping guideline was applied 
for safety and reviewed by the data and safety 
monitoring committee, who endorsed the continuation 
of enrolment from 800 patients to up to 1000 patients. 
Recruiting 1000 patients into the trial (500 in each 
group) would allow differences greater than 8% to be 
detected with 90% power using a two-sided test at 5% 
significance. 1000 patients would also allow detection of 
a levofloxacin-induced three-times increase in C difficile-
positive stools from 5% to 15% between entry to the 
trial and 12 weeks, with 95% power and 5% significance 
(two-sided test).
We analysed the primary endpoint with a log-rank 
comparison, beginning from the date the patient started 
trial treatment to the time of an event, or to censor date for 
those with no events up to 12 weeks. All randomly assigned 
patients were included in an intention-to-treat analysis of 
the primary endpoint, assessed using Kaplan-Meier curves 
and the log-rank test.23 We did prespecified exploratory 
analyses with Cox proportional hazards models to compare 
trial groups after adjustment for stratification variables 
with assumptions for non-proportionality.24 Proportionality 
assumptions were checked by visual inspection of Kaplan-
Meier curves. We generated forest plots to examine the 
treatment effects in prespecified subgroups.
We calculated overall survival from the date the patient 
started trial treatment to the date of death or censoring, 
as appropriate, with all-cause mortality. We assessed 
health care-associated infections with χ² tests with 
continuity adjustments.
Statistical analyses were done with SAS (version 9.4). 
This trial is registered with the ISRCTN registry, number 
ISRCTN51731976, and the EU Clinical Trials Register, 
number 2011-00366-35.
Role of the funding source
The funder and sponsors of the study had no role in 
study design, data collection, data analyses, data inter-
pretation, or writing of the report. The corresponding 
author had full access to the data in the study and with 
SB, TP, GI, and JAD had final responsibility for the 
decision to submit for publication, with the agreement of 
all other authors and the data monitoring and safety 
committee.
Results
Between Aug 15, 2012, and April 29, 2016, we randomly 
assigned 977 patients to receive levofloxacin prophylaxis 
(489 patients) or placebo (488 patients; figure 1; 
appendix pp 1–4). 219 (23%) of 977 patients withdrew 
during the study. Because 207 (21%) of 977 patients 
withdrew during the trial treatment period and recruitment 
was faster than expected, the recruitment target was 
extended to 1000 patients (figure 1). Patient characteristics 
were similar across treatment groups in terms of 
stratification variables, prognostic factors, and anti-
myeloma therapy, with 98% receiving immunomodulatory 
489 allocated to levofloxacin
 477 received allocated intervention 
 12 did not receive allocated intervention
489 analysed for the primary endpoint
109 withdrew within treatment phase 
 50 between 0 and 4 weeks
 35 between 4 and 8 weeks
 24 between 8 and 12 weeks
 
 46 participant choice
 32 other reason
 31 suspected drug toxicity
36 lost to follow-up
 9 withdrew within the follow-up
 phase
488 allocated to placebo 
 475 received allocated intervention 
 13 did not receive allocated intervention
488 analysed for the primary endpoint
98 withdrew within treatment phase 
 54 between 0 and 4 weeks
 30 between 4 and 8 weeks
 14 between 8 and 12 weeks
 
 48 participant choice
 25 other reason
 25 suspected drug toxicity
36 lost to follow-up
 3 withdrew within the follow-up
 phase
2183 patients assessed for eligibility
977 randomly assigned
1206 excluded
  435 not meeting inclusion criteria
 494 declined to participate
 66 other reasons
 211 not known
Figure 1: Trial profile
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imide drugs or proteasome inhibitors (table 1). The median 
patient age was 67 years (IQR 59–75) in the levofloxacin 
group and 67 years (61–75) in the placebo group.
31 (6%) of 489 patients in the levofloxacin group and 
25 (5%) of 488 patients in the placebo group withdrew 
because of suspected drug toxicity, and 15 (2%) of these 
were unblinded. 24 (2%) of 977 total patients took an 
incorrect dose of levofloxacin (or placebo) during a 
4-week block of the 12-week trial period according to their 
estimated glomerular filtration rate results. 40 (4%) of 
Levofloxacin group 
(n=489)
Placebo group 
(n=488)
(Continued from previous column)
Planned anti-myeloma treatment
Thalidomide-based 208 (43%) 216 (44%)
Bortezomib-based 152 (31%) 150 (31%)
Lenalidomide-based 72 (15%) 69 (14%)
Lenalidomide and 
carfilzomib-based
50 (10%) 43 (9%)
Other 7 (1%) 10 (2%)
Bisphosphonate status at randomisation
Not given 68 (14%) 60 (12%)
Given or will be given 419 (86%) 419 (86%)
Missing 2 (<1%) 9 (2%)
Bisphosphonate
Zolendronate 284 (68%) 280 (67%)
Pamidronate 111 (26%) 105 (25%)
Clodronate 14 (3%) 23 (5%)
Other 3 (1%) 7 (2%)
Missing 7 (2%) 4 (1%)
Prophylactic antiviral or antifungal
No 170 (35%) 166 (34%)
Yes 237 (48%) 240 (49%)
Missing 82 (17%) 82 (17%)
Corrected calcium (µmol/L)
<2·50 340 (69%) 354 (73%)
2·50–2·75 102 (21%) 95 (19%)
>2·75 29 (6%) 25 (5%)
Missing 18 (4%) 14 (3%)
Evidence of bone disease
Yes 338 (69%) 351 (72%)
Site of bone disease
Vertebral fracture or 
collapse
118 (24%) 144 (30%)
Lytic lesions 234 (48%) 246 (50%)
Fractured rib 33 (7%) 24 (5%)
Osteoporosis 38 (8%) 37 (8%)
Other fracture 43 (9%) 41 (8%)
Serum β-2-microglobulin (mg/L)
≤4 189 (39%) 192 (39%)
4–8 148 (30%) 152 (31%)
>8 73 (15%) 67 (14%)
Missing 79 (16%) 77 (16%)
Haemoglobin (g/dL)
<7·5 9 (2%) 13 (3%)
7·5–10·0 163 (33%) 166 (34%)
>10·0 315 (64%) 306 (63%)
Missing 2 (<1%) 3 (1%)
(Table 1 continues in next column)
Levofloxacin group 
(n=489)
Placebo group 
(n=488)
Age (years) 67 (59–75) 67 (61–75)
Sex
Male 316 (65%) 295 (60%)
Female 173 (35%) 193 (40%)
Ethnicity
White 452 (92%) 437 (90%)
Mixed 1 (<1%) 2 (<1%)
Asian or British Asian 10 (2%) 17 (3%)
Black or Black British 26 (5%) 28 (6%)
Chinese or other 0 1 (<1%)
Missing 0 3 (1%)
Performance status at randomisation
0 164 (34%) 173 (35%)
1 209 (43%) 188 (39%)
2 80 (16%) 76 (16%)
3 24 (5%) 36 (7%)
4 2 (<1%) 5 (1%)
Missing 10 (2%) 10 (2%)
International Staging System
Stage I 100 (20%) 116 (24%)
Stage II 188 (38%) 165 (34%)
Stage III 121 (25%) 130 (27%)
Missing 80 (16%) 77 (16%)
Estimated glomerular filtration rate (mL/min)
>50 369 (75%) 369 (76%)
20–50 95 (19%) 93 (19%)
<20 25 (5%) 26 (5%)
High-dose CT with planned autologous stem cell transplantation
No 223 (46%) 222 (45%)
Yes 266 (54%) 266 (55%)
Previous infection
Clostridium difficile 2 (<1%) 1 (<1%)
Meticillin-resistant 
Staphylococcus aureus
6 (1%) 7 (1%)
Extended-spectrum 
β-lactamase coliforms
3 (1%) 5 (1%)
Anti-infectives in previous month
No 332 (68%) 331 (68%)
Yes 75 (15%) 76 (16%)
Missing 82 (17%) 81 (17%)
Steroids 14 days before randomisation
Yes 248 (51%) 246 (50%)
Corticosteroids
Prednisolone 24 (5%) 18 (4%)
Dexamethasone 226 (46%) 229 (47%)
Other ·· 2 (<1%)
(Table 1 continues in next column)
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Levofloxacin group 
(n=489)
Placebo group 
(n=488)
(Continued from previous column)
Platelets (× 10⁹/L)
≤150 69 (14%) 79 (16%)
>150 418 (85%) 405 (83%)
Missing 2 (<1%) 4 (1%)
Neutrophils (× 10⁹/L)
<1·8 35 (7%) 55 (11%)
1·8–3·0 138 (28%) 133 (27%)
>3·0 312 (64%) 296 (61%)
Missing 4 (1%) 4 (1%)
Lymphocytes (×10⁹/L)
<1·2 143 (29%) 147 (30%)
1·2–1·8 165 (34%) 170 (35%)
>1·8 177 (36%) 167 (34%)
Missing 4 (1%) 4 (1%)
Serum creatinine (µmol/L)
<130 387 (79%) 384 (79%)
130–199 57 (12%) 54 (11%)
>199 42 (9%) 43 (9%)
Missing 3 (1%) 7 (1%)
Data are median (IQR) or  n (%).
Table 1: Patient characteristics
977 patients required a dose reduction—23 (5%) 
of 489 patients in the levofloxacin group and 17 (3%) of 
488 patients in the placebo group because of a reduction 
in estimated glomerular filtration.
597 serious adverse events were reported up to 16 weeks 
from the start of trial treatment (308 [52%] of 597 total 
events for the 489 patients in the levofloxacin group vs 
289 [48%] of 597 total events for the 488 patients in the 
placebo group), with 537 (90%) reported as unlikely to be 
related or unrelated to study drug (144 unrelated to study 
drug and 126 unlikely to be related to study drug in the 
levofloxacin group; 147 unrelated to study drug and 
120 unlikely to be related to study drug in the placebo 
group), and severity similar between the trial groups 
(appendix p 5). 29 (9%) of 308 serious adverse events in 
the levofloxacin group and 15 (5%) of 289 serious adverse 
events in the placebo group were classed as possibly 
related to drug, eight (3%) of 308 serious adverse events 
in the levofloxacin group and six (2%) of 289 serious 
adverse events in the placebo group were classed as 
probably related to drug, and one (<1%) case of delirium 
definitely related to drug was reported in the levofloxacin 
group. All 105 symptoms associated with these 59 serious 
adverse events that were at least possibly related to trial 
drugs are shown in table 2. Tendonitis was reported in 
five (1%) of 489 patients in the levofloxacin group (vs none 
in the placebo group) and all episodes resolved, although 
three had sequelae reported in the short term. One (<1%) 
case of suspected levofloxacin-induced confusion reversed 
on stopping the drug. All serious adverse events were 
Levofloxacin group Placebo group
Grade 1–2 
(n=37)
Grade 3 
(n=26)
Grade 4 
(n=8)
Grade 1–2 
(n=17)
Grade 3 
(n=14)
Grade 4 
(n=3)
Blood and lymphatic system disorders
Anaemia 2 (5%) 2 (8%) 0 0 0 0
Febrile neutropenia 0 0 1 (13%) 0 0 0
Cardiac disorders
Atrial fibrillation 0 1 (4%) 1 (13%) 0 0 0
Sinus bradycardia 1 (3%) 0 0 0 1 (7%) 0
Ear and labyrinth disorders
Vertigo 0 0 0 1 (6%) 0 0
Gastrointestinal disorders
Abdominal distension 0 1 (4%) 0 0 0 0
Abdominal pain 0 0 0 1 (6%) 0 0
Diarrhoea 3 (8%) 2 (8%) 0 3 (18%) 5 (36%) 0
Nausea 3 (8%) 1 (4%) 0 0 0 0
Gastric obstruction 1 (3%) 0 0 0 0 0
Vomiting 3 (8%) 1 (4%) 0 0 1 (7%) 0
Other 0 0 0 1 (6%) 0 0
General disorders and administration site conditions
Chills 1 (3%) 0 0 0 0 0
Fever 5 (14%) 0 0 3 (18%) 2 (14%) 0
Immune system disorders
Allergic reaction 1 (3%) 0 0 0 1 (7%) 0
Infections and infestations
Bladder infection 0 1 (4) 0 0 0 0
Infectious enterocolitis 1 (3%) 0 0 0 0 0
Lung infection 0 2 (8%) 0 0 0 0
Pustular rash 0 0 0 1 (6%) 0 0
Sepsis 0 0 2 (25%) 0 0 1 (33%)
Small intestine infection 0 1 (4%) 0 0 0 0
Injury, poisoning, and procedural complications
Vascular access 
complication
0 1 (4%) 0 0 0 0
Investigations
Increased alanine 
aminotransferase
0 1 (4%) 0 0 1 (7%) 0
Increased creatinine 1 (3%) 0 0 0 0 0
Decreased neutrophil 
count
0 0 1 (13%) 0 0 0
Metabolism and nutrition disorders
Anorexia 0 0 0 1 (6%) 0 0
Dehydration 0 0 0 1 (6%) 0 0
Hypernatraemia 0 0 0 1 (6%) 0 0
Hyponatraemia 0 0 1 (13%) 0 0 0
Musculoskeletal and connective tissue disorders
Chest wall pain 0 0 0 0 1 (7%) 0
Myalgia 1 (3%) 0 0 0 0 0
Neck pain 1 (3%) 0 0 0 0 0
Extremity pain 1 (3%) 0 0 0 0 0
Tendonitis 3 (8%) 2 (8%) 0 0 0 0
Other 0 1 (4%) 0 0 0 0
(Table 2 continues on next page)
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rereviewed independently by two masked investigators 
after alerts from The European Medicines Agency’s 
Pharmacovigilance Risk Assess ment Committee (2018) 
and the US Food and Drug Administration body (2018) 
and no further signal was detected. Other categories of 
serious adverse events were similar between the study 
groups (table 2).
In the levofloxacin group, 95 (19%) first febrile episodes 
or deaths in 489 patients were reported versus 134 (27%) 
in 488 patients in the placebo group (hazard ratio for 
time to first event within 12 weeks [HR] 0·66, 95% CI 
0·51–0·86; p=0·0018; figure 2). Febrile episodes, deaths, 
and febrile episodes with death during the first 12 weeks 
were less frequent in the levofloxacin group than in the 
placebo group (87 [18%] vs 112 [23%] febrile episodes, 
four [1%] vs 15 [3%] deaths, and four [1%] vs 
seven [1%] febrile episodes with death; appendix p 6). A 
prespecified subgroup analysis of time to first febrile 
episode or death within the first 12 weeks of treatment is 
shown in figure 3.
Cox regression analysis showed that treatment with 
levofloxacin was the most important factor in reducing 
febrile episodes or deaths and retained significance even 
when controlling for baseline characteristics. 314 patients 
took co-trimoxazole 960 mg three times per week to 
prevent Pneumocystis jirovecii pneumonia (155 in the 
placebo group and 159 in the levofloxacin group; 
appendix p 10). We recorded only one case of proven 
P jirovecii pneumonia and one possible microbiologically 
unproven case (both in the levofloxacin group), and 
neither of these patients were receiving co-trimoxazole 
prophylaxis. Use of prophylactic low dose co-trimoxazole 
also showed a significant benefit in reducing febrile 
episodes and deaths (HR 0·59, 95% CI 0·44–0·80; 
p=0·0007) and adjustment for co-trimoxazole made little 
difference to the levofloxacin benefit (0·66, 0·51–0·86; 
p=0·0015), indicating that these two variables have 
independent effects (appendix p 10).
Median follow-up was 12 months (IQR 8–13). Log-rank 
analyses showed an overall survival benefit for the use of 
levofloxacin up to 12 weeks, with patients in the 
levofloxacin group having overall survival of 98% (95% CI 
97–99, with 426 of 489 patients known to be surviving) 
versus overall survival in the placebo group of 95% 
(93–97, with 405 of 488 patients known to be surviving; 
p=0·0081), but no survival benefit at 12 months 
(levofloxacin overall survival 90%, 95% CI 87–93 vs 
placebo overall survival 91%, 88–93; p=0·94; 
appendix p 11). We observed no treatment-related deaths. 
An independent review of causes of death did not reveal 
differences between the two trial groups. During the 
12-week trial period, two (25%) of eight patients in the 
levofloxacin group and ten (45%) of 22 in the placebo 
group died while known to be responding to treatment. 
Five (63%) of eight in the levofloxacin group and 14 (64%) 
of 22 patients in the placebo group died with no evidence 
of infection at the time of death. Deaths during the whole 
Levofloxacin group (n=489) Placebo group (n=488)
Grade 1–2 
(n=37)
Grade 3 
(n=26)
Grade 4 
(n=8)
Grade 1–2 
(n=17)
Grade 3 
(n=14)
Grade 4 
(n=3)
(Continued from previous page)
Nervous system disorders
Dizziness 1 (3%) 0 0 0 0 0
Peripheral sensory 
neuropathy
1 (3%) 0 0 0 0 0
Vasovagal reaction 0 1 (4%) 0 0 0 0
Psychiatric disorders
Confusion 1 (3%) 0 0 0 0 0
Delirium 0 0 1 (13%) 0 0 0
Renal and urinary disorders
Acute kidney injury 3 (8%) 0 1 (13%) 1 (6%) 0 1 (33%)
Chronic kidney disease 0 1 (4%) 0 0 0 0
Respiratory, thoracic, and mediastinal disorders
Hypoxia 0 0 0 0 1 (7%) 0
Skin and subcutaneous tissue disorders
Erythroderma 0 0 0 0 1 (7%) 0
Pruritus 1 (3%) 0 0 0 0 0
Maculopapular rash 2 (5%) 4 (15%) 0 1 (6%) 0 0
Skin ulceration 0 0 0 1 (6%) 0 0
Stevens-Johnson 
syndrome
0 0 0 0 0 1 (33%)
Other 0 2 (8%) 0 0 0 0
Missing 0 0 0 1 (6%) 0 0
Vascular disorders
Hypotension 0 1 (4%) 0 0 0 0
Data are n (%; for each column denominator).
Table 2: Treatment-related serious adverse events
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Figure 2: Kaplan-Meier graph of time to febrile episode or death
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12-month trial period were associated with progressive 
myeloma in 29 (73%) of 40 patients in the levofloxacin 
group and 15 (38%) of 39 patients in the placebo group, 
and infection in 15 (38%) of 40 patients in the levofloxacin 
group and 15 (38%) of 39 patients in the placebo group 
(table 3).
Measuring the total number of febrile episodes, 
217 patients had a total of 264 febrile episodes and these 
showed benefit for the use of levofloxacin versus placebo 
with 92 (20%) of 471 patients affected in the levofloxacin 
group versus 125 (27%) of 463 affected in the placebo 
group (p=0·018). There were fewer hospital (88 vs 114) 
and intensive care unit admissions (three vs five) for 
infection in the levofloxacin group versus the placebo 
group. Sites of infection were predominantly reported in 
the respiratory tract (appendix p 7). At study entry, 
respiratory-related comorbidities including chronic 
obstructive pulmonary disease, asthma, and bron-
chiectasis were reported in 75 (15%) of 489 patients in the 
levofloxacin group and 67 (14%) of 488 patients in the 
placebo group.
There were 323 non-febrile infections requiring anti-
infective treatment. These non-febrile infections occurred 
in 249 patients—116 (24%) of 489 patients in the 
levofloxacin group versus 133 (27%) of 488 patients in the 
placebo group (p=0·23). The sites of non-febrile infections 
were less frequent in the respiratory tract (94 [29%] of 323 
lower respiratory tract and 43 [13%] of 323 upper 
respiratory tract) with more urinary tract (38 [13%] of 323) 
and skin and soft tissue infections (42 [13%] of 323) 
reported compared with febrile infections (data will be 
reported in full in a future publication.
112 organisms were isolated during the study (44 [39%] 
in the levofloxacin group vs 68 [61%] in the placebo 
HR (95% CI)
Estimated glomerular filtration rate (mL/min)
   >50
   ≤50
   Stratified
   Interaction between two groups p=0·06
High-dose CT with planned stem-cell transplantation
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Figure 3: Forest plots of time to febrile episode or death in various subgroups
ECOG=Eastern Cooperative Oncology Group. HR=hazard ratio.
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group), comprising 77 bacterial, 20 viral, and 15 candida 
species samples (appendix p 8). Fewer Gram-negative 
organisms were isolated in the levofloxacin group than in 
the placebo group (appendix p 8). 59 (70%) of 84 organisms 
isolated from the levofloxicin group versus 124 (73%) of 
170 organisms isoloated from the placebo group were 
sensitive to a range of antibiotics, although zero of three 
isolates in the levofloxacin group were sensitive to 
fluoroquinolones versus seven (88%) of eight patients in 
the placebo group (appendix p 9). A case of suspected 
pneumocystis pneumonia and a case of microbiologically 
proven pneumocystis pneumonia were reported in 
two (<1%) of 662 patients who had not taken co-
trimoxazole in the levofloxacin group, and there was one 
case of C difficile infection in each of the two trial groups.
Most of the clinical isolates reported by local 
laboratories were bacterial, but 15 (13%) of 112 were 
Candida spp (mainly upper airway or oral infections) and 
20 (18%) of 112 were viral (appendix p 8). There were 
fewer Streptococcus pneumoniae infections (usually 
levofloxacin-sensitive) than we anticipated, with three 
isolates reported in the placebo group and none in the 
levofloxacin group.
2595 stool and 2933 nasal samples were returned. 
We observed similar acquisition rates for carriage of 
C difficile, ESBL Gram-negative coliforms, and MRSA 
between the levofloxacin group and placebo group over 
the 12 weeks of treatment and 4 weeks after treatment 
(table 4). 25 acquisitions of carriage of these organisms 
were found in the levofloxacin group at baseline 
compared with 51 in the placebo group (table 4). This 
difference could not be accounted for by imbalance of 
baseline factors, by use of antibiotics in the month before 
diagnosis (75 [15%] of 489 patients in the levofloxacin 
group vs 76 [16%] of 488 patients in the placebo group), 
or by the use of steroids in the 14 days before trial 
entry (248 [51%] patients in the levofloxacin group vs 
246 [50%] patients in the placebo group). Nevertheless, 
new acquisitions of health care-associated infections 
were similar between the trial groups (40 in the 
levofloxacin group vs 45 in the placebo group).
Discussion
Levofloxacin prophylaxis resulted in significantly fewer 
deaths, febrile episodes, and a longer time to first febrile 
episode or death, than did treatment with placebo. This 
difference remained significant after adjustment for 
baseline prognostic factors, including the use of 
prophylactic co-trimoxazole and when stratifying by 
various subgroups.
Conventionally, studies on antibiotic prophylaxis in 
neutropenia use febrile episodes or infected patients as the 
primary endpoint, because studies are not usually powered 
to show a predicted 2–3% reduction in mortality.10 
Nevertheless, death is an important endpoint and should 
be captured. If febrile episodes alone is the primary 
endpoint, a higher number of deaths in one randomisation 
group might favour this group, since death prevents 
further febrile episodes occurring in this group. Our 
combined primary endpoint overcame this problem.
The TEAMM trial showed a significant reduction in 
deaths with the use of levofloxacin compared with placebo 
within 12 weeks. To our knowledge, no single large well-
conducted study on antibiotic prophylaxis in neutropenia 
has shown a significant reduction in deaths, but meta-
analysis showed a 3% reduction with fluoro quinolones 
and is the basis of several guidelines in patients with 
neutropenia.10,15,17 The reduction in deaths observed in the 
TEAMM study suggests that either the benefit of 
Levofloxacin 
group
Placebo group
Deaths within 12 weeks
Disease status at death
Myeloma in remission or responding 2/8 (25%) 10/22 (45%)
Myeloma active—progressing 2/8 (25%) 5/22 (23%)
Myeloma active—unknown 4/8 (50%) 7/22 (32%)
Evidence of infection
No 5/8 (63%) 14/22 (64%)
Yes 3/8 (37%) 8/22 (36%)
Deaths between 12 weeks and 52 weeks
Disease status at death
Myeloma in remission or responding 5/32 (16%) 7/17 (41%)
Myeloma active—progressing 27/32 (84%) 10/17 (59%)
Evidence of infection
No 20/32 (63%) 10/17 (59%)
Yes 12/32 (37%) 7/17 (41%)
Deaths between 0 weeks and 52 weeks
Disease status at death
Myeloma in remission or responding 7/40 (17%) 17/39 (44%)
Myeloma active—progressing 29/40 (73%) 15/39 (38%)
Myeloma active—unknown 4/40 (10%) 7/39 (18%)
Evidence of infection
No 25/40 (63%) 24/39 (62%)
Yes 15/40 (37%) 15/39 (38%)
Data are n/N (%).
Table 3: Disease status and evidence of infection at time of death
Levofloxacin group Placebo group
C difficile ESBL MRSA C difficile ESBL MRSA
Present at baseline 
(785 stool, 928 nasal samples)
1 19 5 5 37 9
Week 4 (706 stool, 805 nasal samples) 4 8 0 3 11 4
Week 8 (662 stool, 759 nasal samples) 0 5 1 2 7 1
Week 12 (634 stool, 719 nasal samples) 3 3 1 2 7 2
Week 16 (593 stool, 650 nasal samples) 4 9 2 1 5 0
Total new acquisitions 
(2595 stool, 2933 nasal samples)
11 25 4 8 30 7
ESBL=extended-spectrum β-lactamase. MRSA=methicillin-resistant Staphylococcus aureus.
Table 4: Acquisition of carriage of Clostridium difficile, ESBL, and MRSA organisms
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levofloxacin prophylaxis in newly diagnosed myeloma 
might be greater than in prolonged neutropenia, which 
could be shown in a future meta-analysis, or that our trial 
sample was just sufficient to show a benefit statistically 
and the real size of benefit might be similar to that in 
prolonged neutropenia. Either way, to our knowledge this 
is the first time that the use of prophylactic antibiotics has 
shown a survival benefit in patients with newly diagnosed 
myeloma.
The reduction in early deaths began within the first 
month and continued throughout the 3-month treatment 
period, during which there were 30 deaths. A further 
49 deaths occurred by 12 months, by which time there 
was no survival benefit for the levofloxacin group. There 
may be additional mechanisms underlying the benefits 
of levofloxacin prophylaxis other than a reduction in 
infection. A change in the microbiome might have 
contributed to a reduction in inflammation. In-depth 
studies on the microbiome were not part of this trial but 
are planned for the future. Levofloxacin might have kept 
non-responding patients alive longer than placebo 
patients and once the treatment stopped non-responders 
began to die. If this were the case, continuing levofloxacin 
beyond 12 weeks might keep a patient who did not 
respond to first-line therapy alive long enough to respond 
to second-line therapy.
A 12-week prophylaxis period was chosen from data 
available at trial initiation. These data showed that the 
infection risk was highest in the first 2 months after 
diagnosis with myeloma and reduced as the disease 
responded to treatment and came under control.7 These 
data were from patients treated before the use of novel 
anti-myeloma agents. More recent studies have suggested 
that novel agents and high-dose steroids might contribute 
to a persistent risk of infection, even when myeloma is 
well controlled and this infection risk remains high during 
the first year after diagnosis.6 With the intro duction of 
immunotherapy, induction regimens might become even 
more immunosuppressive and be continued for longer 
periods than at present, increasing the risk of infection-
related death. A continuing infection risk beyond 12 weeks 
raises the question of whether the absence of survival 
benefit at 12 months might be due to early stopping of the 
intervention—12 months of prophylaxis might be 
beneficial.
A limitation of our study is that the total number of 
deaths was small, reflecting a generally well and young 
patient population. 2011–15 population data for England 
showed 79·2% net survival for newly diagnosed patients 
with myeloma at 12 months.9 12-month overall survival 
in our study was 90%, and if adjusted for the risk of 
unrelated death as with net survival, the difference 
between our trial population and real-world population 
survival would be greater. Since our subgroup analysis 
suggested that the benefit of levofloxacin was greatest in 
older and less fit patients, levofloxacin prophylaxis might 
exert a greater benefit once it is adopted in a real-world 
population. Furthermore, since a benefit for prophylaxis 
was shown in a typical trial population that comprises a 
younger, more favourable myeloma prognosis group 
than does real-world patients, there is no patient 
subgroup for which levofloxacin prophylaxis should not 
be recommended. However, some subgroup invest-
igations might have been underpowered. Although a 3% 
reduction in mortality at 12 weeks with levofloxacin 
prophylaxis might seem small, this translates into 
165 deaths prevented in the UK per year. Recommendation 
of levofloxacin prophylaxis should be considered in the 
context of the incidence of local levofloxacin resistance in 
other countries. In the UK in 2017, the prevalence of 
Escherichia coli resistance to fluoroquinolones was 
reported to be 17·5%, but in Italy resistance is 47%.25 
However, such high resistance might not be observed for 
all relevant invasive organisms in myeloma. Prophylactic 
levofloxacin efficacy is likely to be lower in countries with 
high levels of antibiotic resistance. In such countries, 
patient subgroups showing the strongest benefit for 
levofloxacin prophylaxis, namely patients who are not 
eligible for stem cell transplantation and those with 
Eastern Cooperative Oncology Group performance status 
2–4, are still likely to benefit.
Febrile episodes with a temperature of 38°C or greater 
are not a trivial event for patients with myeloma and have 
a major impact on quality of life and health-care costs, as 
patients are requested to attend hospital and are 
frequently admitted. We also collected data on all non-
febrile infections. To our knowledge, data on non-febrile 
infections have not been collected before on such a large 
scale. We observed more non-febrile infections than 
febrile infections (323 non-febrile vs 264 febrile), showing 
such infections also have a substantial burden for 
patients and the health-care system. The clinically 
attributed sites of infection during febrile episodes were 
similarly distributed to those previously reported in the 
literature,26,27 with most being in the respiratory tract.
Levofloxacin was well tolerated, and related serious 
adverse events were rare. European Medicines Agency17 
and US Food and Drug Administration alerts28 have 
highlighted the risk of long-term tendon damage, 
neuropsychiatric concerns, and hypo glycaemia following 
treatment with fluoro quinolones, especially in elderly 
people and largely occurring when the cause of such 
symptoms was not recognised and drug treatment 
continued. Our data showed a less than 1% risk of 
tendonitis with no or mild sequelae after stopping 
levofloxacin, despite our median patient age being 
67 years and most patients receiving high-dose steroids. 
Close clinical supervision and regular reassessment of 
estimated glomerular filtration rate and appropriate 
levofloxacin dose might have been important in 
preventing substantial toxic effects. The benefits of 
levofloxacin outweighed the minimal toxic effects in this 
patient population. Patients who received 250 mg 
levofloxacin because of an estimated glomerular filtration 
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rate of 50 mL/min or less did not derive a benefit of 
levofloxacin prophylaxis in our subgroup analyses. 
Although some hospitals might use levofloxacin 250 mg 
daily for patients with neutropenia, there is no evidence 
that this dose is sufficient and therefore we recommend 
the use of adjusted therapeutic doses of levofloxacin as 
per estimated glomerular filtration rate according to the 
manufacturer’s instructions.
314 patients were given co-trimoxazole 960 mg three 
times per week to prevent P jirovecii infection. There was 
only one confirmed and one microbiologically unproven 
case of P jirovecii infection. A previous antibiotic 
prophylaxis study in patients with myeloma also reported 
no P jirovecii pneumonia in 212 patients, although two-
thirds of patients were not receiving co-trimoxazole.19 
Therefore, we conclude that the risk of P jirovecii 
pneumonia in patients with newly diagnosed myeloma is 
low and probably does not warrant routine treatment 
with prophylactic co-trimoxazole. The finding that 
unrandomised use of low-dose co-trimoxazole might 
have an independent beneficial effect on febrile episodes 
and death is intriguing. Even at a low dose, co-trimoxazole 
might have a prophylactic antibacterial effect and could 
have contributed to the low incidence of S pneumoniae 
infection. Since co-trimoxazole use was unrandomised 
and determined by the treating centre, these findings 
therefore could be spurious and should be interpreted 
with caution. However, the addition of a complementary 
antibiotic could be beneficial and should be investigated 
in future studies.
The difference between our study and previous studies 
in patients with myeloma that reported no benefit for 
antibiotic prophylaxis might be due to the greater 
number of participants in the TEAMM trial and 
differences in the anti-myeloma treatments used. To our 
knowledge, the largest study to date took 10 years to 
recruit 212 patients and most of these patients did not 
receive novel anti-myeloma agents, although some 
received high-dose dexamethasone.19 Our study recruited 
participants rapidly with broad entry criteria that allowed 
all forms of anti-myeloma treatment—98% of our patient 
population received novel agents, which therefore 
reflects current practice. The use of total febrile episodes 
as a primary endpoint might also have contributed to a 
negative study, as previously discussed.
The viral isolates reported in our study are probably an 
under-representation of viral infections, since taking 
specimens for viral identification was not routine practice 
in many district hospitals during the trial period. However, 
the protocol stipulated taking local micro biological 
specimens. The benefit of levofloxacin in reducing 
bacterial infections appears to be largely associated with 
Gram-negative rather than Gram-positive organisms. The 
small number of S pneumoniae infections might have 
partly resulted from 155 placebo patients taking co-
trimoxazole 960 mg three times per week to prevent 
P jirovecii pneumonia. Furthermore, there has been an 
increase in pneumococcal vaccination in the UK, with the 
23-valent polysaccharide pneumo coccal vaccine offered at 
65 years of age since 2003 and herd immunity boosted by 
conjugate pneumococcal vaccines for children younger 
than 5 years with a seven-valent vaccine introduced in 
2006 and 13-valent vaccine introduced in 2010.
The perceived risks of increased carriage of antibiotic-
resistant organisms and health care-associated infections 
were not evident in our study results—we observed 
no increase in colonisation with antibiotic-resistant 
organisms or health care-associated infections in the 
levofloxacin groups, suggesting that there might be 
situations when the use of prophylactic antibiotics 
does not increase the carriage of antibiotic-resistant 
organisms. This observation is supported by large 
reviews and meta-analyses of prospective studies on 
antibiotic prophylaxis10,29 or selective digestive decon-
tamination,30–32 which did not show increased carriage of 
resistant isolates com pared with placebo groups. Our 
study group differs from previous studies because most 
patients were not admitted to hospital in our study.
The main limitation of this study is the high number 
of withdrawals, despite the low toxicity. Around half of the 
withdrawals occurred in the first 4 weeks, and the high 
numbers might reflect poor commitment of patients with 
newly diagnosed myeloma to a supportive care placebo-
controlled trial, possibly because they prioritise focusing 
on disease control. Patients had to collect stool samples 
every 4 weeks, take their temperatures daily, and fill in a 
diary, which might have been burdensome. Myeloma XI33 
was an open-label randomised trial of anti-myeloma 
therapies that ran concurrently with TEAMM, recruited at 
three times the rate of TEAMM, and had fewer withdrawals. 
40% of the patients in the TEAMM trial were also enrolled 
in Myeloma XI and prioritised compliance with active anti-
myeloma therapy rather than placebo-controlled infection 
prophylaxis. A previous supportive care trial in patients 
with myeloma who received oral clodronic acid or placebo 
had higher withdrawal than the TEAMM trial (209 [39%] 
of 536 patients).34 High withdrawal could be a feature of 
placebo-controlled supportive care trials and might require 
consideration in future recruitment targets. However, once 
an intervention is observed to be effective in reducing 
deaths, as levofloxacin was in this trial, compliance might 
be expected to be good. Suspected drug toxic effects 
accounted for a quarter of withdrawals in the TEAMM trial 
and were balanced between the study groups, suggesting 
that perceived rather than actual toxic effects might have 
contributed to the large number of withdrawals.
In summary, our study found a consistent benefit for 
the use of levofloxacin prophylaxis over 12 weeks in 
patients with newly diagnosed myeloma, without any 
increased in health care-associated infections. Thus, 
patients with newly diagnosed myeloma could benefit 
from levofloxacin prophylaxis, although local antibiotic 
resistance proportions must be considered. Prolonged 
antibiotic prophylaxis after 12 weeks and combined 
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antibiotic use for prophylaxis requires investigation in 
future studies.
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